Immunotherapy plus chemotherapy after surgery for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had surgery to remove your lung cancer, and the pathologist found small cell lung cancer in the removed tissue.
- You must be generally well enough to care for yourself (score 0 or 1 on a standard health scale).
- Your major organs (liver, kidneys, blood) must be working normally.
- You must not have had any other cancer in the past 5 years.
- You must not have active autoimmune diseases, active hepatitis B, hepatitis C, HIV, or interstitial lung disease.
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control during the trial and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) and chemotherapy for people with advanced small cell lung cancer that has progressed after previous treatments. It aims to see if this combination can help control the cancer.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after lung cancer surgery can help stop the cancer from coming back. It is for people with non-small cell lung cancer that has not spread to the brain and does not have certain genetic changes (EGFR/ALK mutations).
Hear when a new Postoperative Incidental Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.